MK-4482
Biological
Merck Sharp & Dohme Corporation
Total Payments
$1.5M
Transactions
234
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.5M | 234 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.5M | 231 | 99.6% |
| Consulting Fee | $6,175 | 3 | 0.4% |
Payments by Type
Research
$1.5M
231 transactions
General
$6,175
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19. | Merck Sharp & Dohme Corporation | $1.1M | 0 |
| A Phase 2,3 Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19 | Merck Sharp & Dohme Corporation | $330,575 | 0 |
Top Doctors Receiving Payments for MK-4482
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Tacoma, WA | $1.5M | 231 |
| Janet Englund | Pediatric Infectious Diseases | Seattle, WA | $2,975 | 1 |
| , MD | Infectious Disease | Chapel Hill, NC | $1,700 | 1 |
| , MD | Internal Medicine | Baltimore, MD | $1,500 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $1.5M
- Total Doctors 3
- Transactions 234
About MK-4482
MK-4482 is a biological associated with $1.5M in payments to 3 healthcare providers, recorded across 234 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2020 to 2020. In 2020, $1.5M was paid across 234 transactions to 3 doctors.
The most common payment nature for MK-4482 is "Unspecified" ($1.5M, 99.6% of total).
MK-4482 is associated with 2 research studies, including "A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19." ($1.1M).